IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Visuals

Visual guide

Diagrams and infographics for quickly understanding Iboga, Ibogaine, Noribogaine, analogs, safety, evidence, history, and coverage status.

Visual field guide

IbogaBase uses visuals to clarify source categories and risk, not to decorate the topic or borrow sacred imagery. Each diagram should make a reader more accurate in the next click.

Four lanes

PlantIboga

Central African plant, living traditions, conservation, stewardship.

AlkaloidIbogaine

Studied compound with serious safety and legal constraints.

MetaboliteNoribogaine

Development focus. Investigational study permission is not approval.

DerivativesAnalogs

18-MC, tabernanthalog, and related compounds tracked separately.

Each lane has different evidence, law, safety, source context, and cultural meaning.

Safety risk map

QT/QTc

Read heart rhythm risk first.

Electrolytes

Dehydration and imbalance can matter.

CYP2D6

Metabolism and interactions need review.

Medications

QT-prolonging, serotonergic, stimulant, sedative, and opioid contexts matter.

Psychiatric risk

Suicidality, mania, psychosis, and destabilization need screening.

Emergency readiness

Monitoring and response capacity are part of the evidence conversation.

Evidence strength

Opioid use disorderEarly human and observational Alcohol use disorderVery limited human evidence Traumatic brain injuryLimited observational evidence PTSD and trauma symptomsLimited observational evidence Depression and mood symptomsVery limited human evidence Parkinson's diseaseSingle case report only WithdrawalLimited observational evidence CravingsLimited observational evidence

History markers

  1. Multiple public accounts describe ancestral vision, forest observation, and animal-root stories.

  2. Written European documentation of Bwiti and Iboga appears much later than oral knowledge.

  3. Howard Lotsof reports unexpected interruption of heroin withdrawal and craving after Ibogaine.

  4. Hunter S. Thompson's Ed Muskie Ibogaine rumor enters U.S. political-media mythology.

  5. Lotsof's U.S. patent records the anti-addiction method claim; a patent is not clinical proof.

  6. Veteran TBI studies, state policy activity, and Noribogaine IND news accelerate public attention.

Coverage audit

Canonical topics27

required history, culture, safety, law, and media coverage

Mapped0

visible or searchable in the current site

Under review1

known gaps or items needing stronger sources

Sources815

public records indexed for search